Navigation Links
Scarred for Life? Synedgen Hopes Not
Date:6/4/2013

Claremont, CA (PRWEB) June 04, 2013

Because burns tend to heal slowly, become infected and remain inflamed, they can produce scars that are excessive, physically debilitating and functionally damaging. Each year in the US, more than 1 million burn injuries require medical attention. While over the last several decades advances in life saving technology have improved outcomes for burn patients, methods to prevent scar formation have not kept pace.

With support from the US Army Medical Research and Materiel Command, Synedgen is working to accelerate the burn healing process. This contract will expand Synedgen’s pipeline wound care portfolio and facilitate studies to further demonstrate the extent of Synedgen’s novel polysaccharide derivative to reduce inflammation and provide enhanced healing with the reduction of scarring. Funding will also support analysis of cellular mechanisms of scar formation and how the product mitigates this process.

“There is an urgent need to address wound healing and scar reduction in burn patients, and we are eager to continue our product development to improve outcomes for these patients,” stated Synedgen president Shenda Baker. “Synedgen’s product has been demonstrated in vivo and in vitro to reduce inflammation and infection in dermal wounds and to increase healing with significant reduction of scar tissue. The product is designed to control the inflammation, both due to tissue damage and to bacteria, and accelerate the regenerative environment to prevent the emergence of excessive scar formation.”

This work is supported by the US Army Medical Research and Materiel Command under Contract No. W81XWH-13-C-0053. The views, opinions and/or findings contained in this release are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

About Synedgen

Synedgen Inc. is an innovative pharmaceutical company focused on developing novel therapies and products through its proprietary biomaterials technology platform. Product development is targeted to specifically address unmet needs for therapies to treat inflammation, damage or infection at dermal, pulmonary and gastrointestinal surfaces.

Synedgen’s Corporate Headquarters, Research Laboratories and Manufacturing Facility are in Claremont CA. Additional information can be found at Synedgen’s web site at http://www.synedgen.com

Read the full story at http://www.prweb.com/releases/2013/6/prweb10796834.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Synedgen’s Synoplex® Receives FDA Indexing for Use in the Treatment of Chronic Wounds in Pachyderms
2. Synedgen Announces Issuance of Patent to Optimize Animal Health
3. Synedgen Announces Effective Treatment Against Bacterial Biofilms in Minor Animal Species
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology ... drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription ... is able to cross the cell membrane and bind intracellular STAT3 and inhibit ...
(Date:10/10/2017)... firm Parks Associates announced today that Tom Kerber , ... Meeting , October 11 in Scottsdale, Arizona . Kerber ... smart safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and the introduction ...
(Date:10/9/2017)... ... ... The award-winning American Farmer television series will feature 3 Bar Biologics in ... 8:30aET on RFD-TV. , With global population estimates nearing ten billion people by ... feed a growing nation. At the same time, many of our valuable resources are ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... Hi-C-based genomic technologies, launched its ProxiMeta™ Hi-C metagenome deconvolution product, featuring the ... and accompanying cloud-based bioinformatics software to perform Hi-C metagenome deconvolution using their ...
Breaking Biology Technology:
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
(Date:3/28/2017)... 28, 2017 The report "Video ... Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), and ... Global Forecast to 2022", published by MarketsandMarkets, the market ... is projected to reach USD 75.64 Billion by 2022, ... The base year considered for the study is 2016 ...
Breaking Biology News(10 mins):